The FDA has expanded the indication of once-weekly basal insulin icodec-abae to include children and adolescents aged 10 years and older with type 2 diabetes.
Mean percentage of time that CGM-measured glucose level was in range of 70 to 180mg/dL was 21 percentage points higher with CGM ...
The conversion from accelerated to traditional approval updates the tumor mutational burden threshold from 10 to 13 mutations ...
Strong recommendations include distinguishing bothersome from nonbothersome tinnitus, asking about risks for self-harm.
HealthDay News — Antipsychotic treatment initiation is associated with rapid increases in hemoglobin A1c (HbA1c) and weight, according to a study published in the November issue of The Lancet ...
The new 150mg oral pellet formulation provides a capsule-free prophylactic option for adults and adolescents with hereditary ...
The investigational vaccine targets pathological amyloid-beta to lower brain amyloid in patients with preclinical Alzheimer ...
Accelerated approval is supported by 34-week interim data from the phase 3 I CAN trial showing a statistically significant 43% placebo-adjusted reduction in proteinuria.
Enzyme-inducing ASDs increase risk for incident osteoporosis or osteopenia, but few patients receive vitamin D supplementation.
Patients with baseline viral suppression maintained viral suppression, while those without achieved viral suppression by 13 ...
A review of 5 investigational therapies with target action dates in November 2026, spanning neurology, gastroenterology, and oncology.
The FDA has approved Hibsago (bepirovirsen) as an add-on antisense oligonucleotide therapy to help noncirrhotic adults with chronic hepatitis B achieve functional cure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results